Article
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2011
Ludovini Vienna, Bianconi Fortunato, Pistola Lorenza, Chiari Rita, Minotti Vincenzo, Colella Renato, Giuffrida Dario, Tofanetti Francesca Romana, Siggillino Annamaria, Flacco Antonella, Baldelli Elisa, Iacono Daniela, Mameli Maria Grazia, Cavaliere Antonio, Crinò Lucio
Abstract excerpt
BACKGROUND: Specific mutations of the epidermal growth factor receptor (EGFR) gene are predictive for favorable response to tyrosine kinase inhibitors (TKIs) and are associated with a good prognosis. In contrast, Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation has been shown to predict poor response to such therapy. Nevertheless, tumor that initially responds to EGFR-TKIs almost inevitably becomes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.